Skip Navigation


Annals of Oncology Advance Access originally published online on July 10, 2006
Annals of Oncology 2007 18(2):215-225; doi:10.1093/annonc/mdl155
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
18/2/215    most recent
mdl155v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Beslija, S
Right arrow Articles by Zwierzina, H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Beslija, S
Right arrow Articles by Zwierzina, H
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

reviews

Second consensus on medical treatment of metastatic breast cancer

S Beslija, J Bonneterre, H Burstein, V Cocquyt, M Gnant, P Goodwin, V Heinemann, J Jassem, WJ Köstler, M Krainer, S Menard, T Petit, L Petruzelka, K Possinger, P Schmid, E Stadtmauer, M Stockler, S Van Belle, C Vogel, N Wilcken, C Wiltschke, CC Zielinski* and H Zwierzina

Central European Cooperative Oncology Group (CECOG)§, Schwarzspanierstrasse 7/5, A-1090 Vienna, Austria

* Correspondence to: Prof. C. C. Zielinski, Director, Department of Medicine I and Clinical Division of Oncology, Medical University of Vienna, 18–20 Waehringer Guertel, A – 1090 Vienna, Austria. Tel: +43 (1) 40400–4445; Fax: +43 (1) 440400–4451; E-mail: christoph.zielinski{at}meduniwien.ac.at

The present consensus manuscript defines evidence-based recommendations for state-of-the-art treatment of metastatic breast cancer depending on disease-associated and biologic variables.

Key words: chemotherapy, endocrine therapy, medical treatment, metastatic breast cancer, targeted therapy

Abbreviations: MBC, metastatic breast cancer • ER, estrogen receptor • PgR, progesterone receptor • IHC, immunohistochemistry • FISH, fluorescence in situ hybridisation • CISH, chromogenic in situ hybridization • TTP, time to progression • ORR, overall response rate • OS, overall survival

§ Affiliations of individual authors are provided in the Appendix.

Received for publication February 20, 2006. Revision received May 26, 2006. Accepted for publication May 26, 2006.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
R. Bartsch, C. Wenzel, G. Altorjai, U. Pluschnig, M. Rudas, R. M. Mader, M. Gnant, C. C. Zielinski, and G. G. Steger
Capecitabine and Trastuzumab in Heavily Pretreated Metastatic Breast Cancer
J. Clin. Oncol., September 1, 2007; 25(25): 3853 - 3858.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. Verma and M. Clemons
First-Line Treatment Options for Patients with HER-2 Negative Metastatic Breast Cancer: The Impact of Modern Adjuvant Chemotherapy
Oncologist, July 1, 2007; 12(7): 785 - 797.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.